• Clinical Trials - Multiple Sclerosis (MS)

    Study Objective Contact
    A Multicenter, Global, Observational Study to Collect Information on Safety and to Document the Drug Utilization of Tecfidera™ (dimethyl fumarate) when Used in Routine Medical Practice in the Treatment of Multiple Sclerosis (ESTEEM) [LCID Study Number: 2014-002] This study is being done to gain a better understanding of the benefits and risks of long term treatment with Tecfidera (dimethyl fumarate) in patients with Multiple Sclerosis (MS). The main purpose of this observational study is to collect information on any side effects that may occur in patients taking Tecfidera. Principal Investigator(s):
    Claudia J. Chaves, MD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Rik Ganguly.
    A Multicenter, Observational, Open-Label, Single- Arm Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients [LCID Study Number: 2012-001] Purpose: An observational study to determine which questionnaires and tests predict disease-free states for patients who are using Tysabri to treat early stages of Multiple Sclerosis. For more information on this study, please visit: http://www.lahey.org/Departments_and_Locations/Departments/Neurology/Research/Multiple_Sclerosis_Trials.aspx Principal Investigator(s):
    Claudia J. Chaves, MD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Nicholas F. Ventura,
    Rik Ganguly.
    A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects with Secondary Progressive Multiple Sclerosis, with optional open-label Extension [LCID Study Number: 2011-036] Purpose: To determine whether or not Tysabri is effective in reducing disability progression for Secondary Progressive Multiple Sclerosis (SPMS) patients as compared to Placebo. For more information on this study, please visit: http://www.lahey.org/Departments_and_Locations/Departments/Neurology/Research/Multiple_Sclerosis_Trials.aspx Principal Investigator(s):
    Ann Camac, MD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Rik Ganguly.
    An Open-Label, Two-Arm, Randomized Study to Characterize Flu-Like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning from Current Interferon Beta Therapies to BIIB017 [LCID Study Number: 2013-073] The purpose of this study is to test the effectiveness, safety and side effects of an experimental medication called BIIB017 that is being developed for patients with Multiple Sclerosis (MS). The purpose of the study is to find out if patients with relapsing MS (RMS) experience new and/or increased flu-like symptoms after switching from standard therapies (Avonex®, Betaseron®, Rebif®) to the investigational medication, BIIB017 Principal Investigator(s):
    Ann Camac, MD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Rik Ganguly.